Abstract
Since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981, AIDS, as the global disease affecting 33.2 million people in 2007, has always been an unsolved problem worldwide. Reverse transcriptase (RT) is a crucial enzyme in the life cycle of human immunodeficiency virus type 1 (HIV-1), and thereby has been the prime drugs target for antiretroviral (ARV) therapy against AIDS. To date, two classes of RT inhibitors (RTIs), e.g., nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), and a lot of compounds tested as RTIs have been described. To our knowledge, bis(heteroaryl)piperazines (BHAPs) have been considered as one class of promising NNRTIs, such as structurally and chemically related NNRTI delavirdine, which was approved by the U. S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in 1997. In this minireview, we make attempts to report the progress of synthesis and structure – activity relationship (SAR) of BHAPs, in the meantime, the synergistic inhibition of HIV-1 replication by combining delavirdine with other HIV-1 inhibitors is also discussed. It will pave the way for the design and development of BHAPs as anti-HIV-1 agents in AIDS chemotherapy in the future.
Keywords: Bis(heteroaryl)piperazine, synthesis, acquired immunodeficiency syndrome, human immunodeficiency virus type 1, non-nucleoside reverse transcriptase inhibitor, structure, –, activity relationship
Mini-Reviews in Medicinal Chemistry
Title: Progress of Bis(heteroaryl)piperazines (BHAPs) as Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) against Human Immunodeficiency Virus Type 1 (HIV-1)
Volume: 10 Issue: 1
Author(s): Hui Xu
Affiliation:
Keywords: Bis(heteroaryl)piperazine, synthesis, acquired immunodeficiency syndrome, human immunodeficiency virus type 1, non-nucleoside reverse transcriptase inhibitor, structure, –, activity relationship
Abstract: Since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981, AIDS, as the global disease affecting 33.2 million people in 2007, has always been an unsolved problem worldwide. Reverse transcriptase (RT) is a crucial enzyme in the life cycle of human immunodeficiency virus type 1 (HIV-1), and thereby has been the prime drugs target for antiretroviral (ARV) therapy against AIDS. To date, two classes of RT inhibitors (RTIs), e.g., nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), and a lot of compounds tested as RTIs have been described. To our knowledge, bis(heteroaryl)piperazines (BHAPs) have been considered as one class of promising NNRTIs, such as structurally and chemically related NNRTI delavirdine, which was approved by the U. S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in 1997. In this minireview, we make attempts to report the progress of synthesis and structure – activity relationship (SAR) of BHAPs, in the meantime, the synergistic inhibition of HIV-1 replication by combining delavirdine with other HIV-1 inhibitors is also discussed. It will pave the way for the design and development of BHAPs as anti-HIV-1 agents in AIDS chemotherapy in the future.
Export Options
About this article
Cite this article as:
Xu Hui, Progress of Bis(heteroaryl)piperazines (BHAPs) as Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) against Human Immunodeficiency Virus Type 1 (HIV-1), Mini-Reviews in Medicinal Chemistry 2010; 10 (1) . https://dx.doi.org/10.2174/138955710791112578
DOI https://dx.doi.org/10.2174/138955710791112578 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Composite Study of Coagulation Milieu in Covid-19: Experience from a
Tertiary Care Centre from India
Cardiovascular & Hematological Disorders-Drug Targets The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19
Current Pharmaceutical Design Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Vitamin C and D Supplements to Prevent the Risk of COVID-19
The Natural Products Journal Patent Landscape of Countermeasures Against Smallpox and Estimation of Grant Attraction Capability Through Patent Landscape Data
Recent Patents on Anti-Infective Drug Discovery CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer’s Disease
Current Medicinal Chemistry Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents
Letters in Drug Design & Discovery Amniotic Fluid Embolism: Review
Current Pharmaceutical Biotechnology QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Current Pharmaceutical Design Copper-catalyzed Convenient Synthesis and SAR Studies of Substituted-1,2,3-triazole as Antimicrobial Agents
Letters in Drug Design & Discovery Identification of the First “Two Digit Nano-molar” Inhibitors of the Human Glyoxalase-I Enzyme as Potential Anticancer Agents
Medicinal Chemistry Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Design, Synthesis, Molecular Docking and <i>In vitro</i> Biological Evaluation of Benzamide Derivatives as Novel Glucokinase Activators
Current Enzyme Inhibition Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry Development of Neurochemical Normalization (“Agonist Substitution”) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909
Current Medicinal Chemistry - Central Nervous System Agents Mixed Lineage Kinase Family, Potential Targets for Preventing Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry